JP2016540505A - アデノウイルス発現免疫細胞刺激受容体アゴニスト - Google Patents

アデノウイルス発現免疫細胞刺激受容体アゴニスト Download PDF

Info

Publication number
JP2016540505A
JP2016540505A JP2016533143A JP2016533143A JP2016540505A JP 2016540505 A JP2016540505 A JP 2016540505A JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016540505 A JP2016540505 A JP 2016540505A
Authority
JP
Japan
Prior art keywords
adenovirus
cells
cancer
replication competent
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016533143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540505A5 (enExample
Inventor
フランク トゥファロ，
フランク トゥファロ，
フアン フエヨ−マルガレト，
フアン フエヨ−マルガレト，
カンデラリア ゴメス−マンサノ，
カンデラリア ゴメス−マンサノ，
チャールズ コンラッド，
チャールズ コンラッド，
ダブリュー．ケー． アルフレッド ユン，
ダブリュー．ケー． アルフレッド ユン，
ホン ジアン，
ホン ジアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2016540505A publication Critical patent/JP2016540505A/ja
Publication of JP2016540505A5 publication Critical patent/JP2016540505A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016533143A 2013-11-22 2014-11-21 アデノウイルス発現免疫細胞刺激受容体アゴニスト Withdrawn JP2016540505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907860P 2013-11-22 2013-11-22
US61/907,860 2013-11-22
PCT/US2014/066920 WO2015077624A1 (en) 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019238013A Division JP2020048582A (ja) 2013-11-22 2019-12-27 アデノウイルス発現免疫細胞刺激受容体アゴニスト

Publications (2)

Publication Number Publication Date
JP2016540505A true JP2016540505A (ja) 2016-12-28
JP2016540505A5 JP2016540505A5 (enExample) 2017-12-28

Family

ID=53180213

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016533143A Withdrawn JP2016540505A (ja) 2013-11-22 2014-11-21 アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2019238013A Pending JP2020048582A (ja) 2013-11-22 2019-12-27 アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2021097883A Pending JP2021137029A (ja) 2013-11-22 2021-06-11 アデノウイルス発現免疫細胞刺激受容体アゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019238013A Pending JP2020048582A (ja) 2013-11-22 2019-12-27 アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2021097883A Pending JP2021137029A (ja) 2013-11-22 2021-06-11 アデノウイルス発現免疫細胞刺激受容体アゴニスト

Country Status (11)

Country Link
US (4) US20160289645A1 (enExample)
EP (2) EP3653714A1 (enExample)
JP (3) JP2016540505A (enExample)
KR (1) KR20160137946A (enExample)
CN (2) CN106029889A (enExample)
AU (1) AU2014352749A1 (enExample)
CA (1) CA2931322A1 (enExample)
DK (1) DK3071697T3 (enExample)
ES (1) ES2765489T3 (enExample)
SG (1) SG10201907841UA (enExample)
WO (1) WO2015077624A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528890A (ja) * 2017-07-21 2020-10-01 シァメン・ユニヴァーシティ 腫瘍を治療するためのウイルス
JP2022501339A (ja) * 2018-09-15 2022-01-06 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
JP6744318B2 (ja) * 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
MY183703A (en) 2015-04-30 2021-03-09 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
KR20180108590A (ko) 2015-12-17 2018-10-04 싸이오서스 테라퓨틱스 엘티디. 항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN119592523A (zh) 2016-08-29 2025-03-11 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
DK3293201T3 (da) * 2016-09-12 2020-12-07 Targovax Oy Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
AU2017375958A1 (en) * 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CA3048185A1 (en) * 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
GB2578394A (en) 2017-08-07 2020-05-06 Univ California Platform for generating safe cell therapeutics
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2019191494A1 (en) 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP2022521268A (ja) * 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
AU2020325825A1 (en) 2019-08-05 2022-03-17 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
CA3170045A1 (en) * 2020-03-06 2021-09-10 Saumendra N. SARKAR Irf modulator-expressing oncolytic viruses for treating cancer
EP4164683A4 (en) * 2020-06-10 2025-03-26 Richard Lowenthal GENETICALLY ENGINEERED ADENOVIRUS VECTORS AND USES THEREOF
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230293590A1 (en) 2020-08-10 2023-09-21 Mesoblast International Sárl Cellular compositions and methods of treatment
JP7614980B2 (ja) 2021-08-25 2025-01-16 三菱重工航空エンジン株式会社 燃焼器パネル、及びガスタービン用燃焼器
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504959A (ja) * 2008-10-08 2012-03-01 イントレキソン コーポレーション 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
WO2013116778A2 (en) * 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
JP2013541945A (ja) * 2010-09-24 2013-11-21 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解性アデノウイルスベクターならびにそれに関連する方法および使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE69628744D1 (de) 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
WO1999028349A2 (en) * 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
JP2005515784A (ja) * 2002-02-01 2005-06-02 トランジェーヌ、ソシエテ、アノニム Ｐｏｄに関連した細胞活性を調節するためのアデノウイルスベクター
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2005010151A2 (en) 2003-06-27 2005-02-03 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
SI2650020T1 (sl) 2005-05-06 2017-03-31 Providence Health & Services - Oregon Technology Transfer Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
EP2662383A1 (en) 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
HUE031371T2 (en) * 2010-08-23 2017-07-28 Univ Texas Anti-ox40 antibodies and methods of using the same
EP2675933B1 (en) * 2011-02-17 2017-02-08 Alcoa Inc. 2xxx series aluminum lithium alloys
JP6415977B2 (ja) * 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
CN104427992B (zh) * 2012-01-25 2017-12-19 德那翠丝有限公司 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504959A (ja) * 2008-10-08 2012-03-01 イントレキソン コーポレーション 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
JP2013541945A (ja) * 2010-09-24 2013-11-21 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解性アデノウイルスベクターならびにそれに関連する方法および使用
WO2013116778A2 (en) * 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH 64, 3281-3287, MAY 1, 2004, JPN6018038226, 2004, ISSN: 0004104659 *
加齢医学研究所雑誌, JPN6018038229, 15 February 2008 (2008-02-15), pages 57, ISSN: 0004104661 *
第６２回 日本癌学会総会記事, JPN6018038228, 25 August 2003 (2003-08-25), pages 417, ISSN: 0004104660 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528890A (ja) * 2017-07-21 2020-10-01 シァメン・ユニヴァーシティ 腫瘍を治療するためのウイルス
JP7144915B2 (ja) 2017-07-21 2022-09-30 シァメン・ユニヴァーシティ 腫瘍を治療するためのウイルス
US11793844B2 (en) 2017-07-21 2023-10-24 Xiamen University Virus for treatment of tumor
JP2022501339A (ja) * 2018-09-15 2022-01-06 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
JP7480126B2 (ja) 2018-09-15 2024-05-09 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
JP2024109583A (ja) * 2018-09-15 2024-08-14 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス

Also Published As

Publication number Publication date
JP2021137029A (ja) 2021-09-16
DK3071697T3 (da) 2020-01-27
EP3071697B1 (en) 2019-10-16
KR20160137946A (ko) 2016-12-02
CN114317461A (zh) 2022-04-12
US20160289645A1 (en) 2016-10-06
US20210301264A1 (en) 2021-09-30
CN106029889A (zh) 2016-10-12
CA2931322A1 (en) 2015-05-28
ES2765489T3 (es) 2020-06-09
JP2020048582A (ja) 2020-04-02
EP3071697A4 (en) 2017-05-17
EP3071697A1 (en) 2016-09-28
SG10201907841UA (en) 2019-10-30
EP3653714A1 (en) 2020-05-20
US20190093085A1 (en) 2019-03-28
US20250171745A1 (en) 2025-05-29
WO2015077624A1 (en) 2015-05-28
AU2014352749A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
US20250171745A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
US11090344B2 (en) Adenovirus and immunomodulator combination therapy
JP6325459B2 (ja) 腫瘍関連異種抗原を発現するアデノウイルス
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
Spunde et al. Recombinant viral vectors for therapeutic programming of tumour microenvironment: Advantages and limitations
Lu et al. Modulating oncolytic adenovirus immunotherapy by driving two axes of the immune system by expressing 4-1bbl and cd40l
US10973875B2 (en) Medical agents and uses thereof
CN111849905B (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
US20250064873A1 (en) TNFSF-L Fusion Proteins and Uses Thereof
HK40030022A (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
HK1230236A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
HK40104197A (zh) Tnfsf-l融合蛋白及其用途
WO2022262765A1 (zh) 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
Guinn et al. International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China
WO2022011651A1 (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
HK40007925A (en) Adenovirus and immunomodulator combination therapy
IL315626A (en) Novel usage of oncolytic gene-modified measles virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200123

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200127